Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, taking place Oct. 19-21, 2026, in Amsterdam, Netherlands. The presentation, scheduled for Oct. 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. This announcement is significant as it underscores Tonix's commitment to advancing innovative vaccine solutions amid rising global health threats.
The World Vaccine Congress Europe is a premier event that brings together leading experts, researchers, and industry stakeholders to discuss the latest developments in vaccine research and development. Tonix's participation highlights its role in the vaccine landscape and provides a platform to showcase its novel approach to combating infectious diseases. The TNX-801 platform, based on horsepox virus, is designed to be safe and effective, potentially offering advantages over existing vaccines. By presenting at this congress, Tonix can gather feedback, attract potential collaborators, and enhance its visibility in the global health community.
In addition to the oral presentation, Tonix will lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on Oct. 20 at 11:30 a.m. CEST. This session will allow Tonix to engage with peers and experts on the challenges and opportunities in vectored vaccine development, further positioning the company as a thought leader in the field. The implications of this announcement extend beyond the immediate event; successful development of TNX-801 could contribute to global efforts to control mpox outbreaks and prepare for future pandemics.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For investors and industry observers, Tonix's presentation at the World Vaccine Congress Europe is a key event to watch. It not only demonstrates the company's progress in vaccine development but also its strategic focus on immunology, which could drive long-term growth. The company's diverse pipeline, spanning CNS and immunology, positions it well to address multiple high-value markets. As Tonix continues to advance TNX-801 and other candidates, its ability to secure partnerships and funding may be enhanced, ultimately benefiting shareholders.
To view the full press release, visit https://ibn.fm/BHVjU. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries.
